A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

August 28, 2019

Study Completion Date

August 28, 2019

Conditions
Alzheimer Disease
Interventions
BIOLOGICAL

LY3002813

Administered IV

DRUG

Placebo

Administered IV

Trial Locations (9)

21201

SNBL Clinical Pharmacology Center Inc, Baltimore

32162

Compass Research, The Villages

32806

Compass Research, Orlando

33445

Brain Matters Research, Delray Beach

63141

St. Louis Clinical Trials, LC, St Louis

84106

PRA Health Sciences, Salt Lake City

162-0053

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku

169-0073

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku

130-0004

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Sumida-ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02624778 - A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD | Biotech Hunter | Biotech Hunter